FORM 6-K
  SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending December 2009
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 

 

 

GSK completes extension of strategic collaboration with Aspen

 

London, UK - December 1st, 2009: GSK announced that yesterday it completed the extension of its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and the acquisition of a minority shareholding in the South African based pharmaceuticals company. This is part of a wide ranging agreement which includes combining commercial activities in Sub-Saharan Africa and the divestment of several assets to Aspen.

 

On completion, Aspen issued 68.5 million ordinary shares to GSK in consideration for the transfer of assets. Taken together with Aspen shares acquired by GSK between signing and closing, this issue takes GSK's holding in Aspen to a total of 81.7million shares, the equivalent of a 19% shareholding.  

 

In addition, Abbas Hussain, President Emerging Markets, GlaxoSmithKline will be appointed to Aspen's Board of Directors as a non-executive director with effect from 7th December.

 

S M Bicknell

Company Secretary

01 December 2009

 

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

 

Enquiries:

    

UK Media enquiries:

Philip Thomson

(020) 8047 5502
 

Claire Brough

(020) 8047 5502
 

Stephen Rea

(020) 8047 5502
 

Alexandra Harrison

(020) 8047 5502
 

Gwenan White

(020) 8047 5502
     

US Media enquiries:

Nancy Pekarek

(919) 483 2839
 

Mary Anne Rhyne

(919) 483 2839
 

Kevin Colgan

(919) 483 2839
 

Sarah Alspach

(919) 483 2839
     

European Analyst/Investor enquiries:

David Mawdsley

(020) 8047 5564
 

Sally Ferguson

(020) 8047 5543
 

Gary Davies

(020) 8047 5503
     

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419
 

Jen Hill Baxter

(215) 751 7002


    

Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk Factors' in the 'Business Review' in the company' s Annual Report on Form 20-F for 2008.


Registered in England & Wales:

No. 3888792
 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS


 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: December 01 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc